Thanks @spnc, always good to see what the competition are saying. A few summary points/ thoughts from me:
They think the TAM for prostate imaging is US$1.6b rising to US$3b by 2028. Current total annualised sales for LNTH and TLX were US$1.2b. Interesting that their predicted TAM is more optimistic than TLX's US$2.3b.
They reported ~US$100m net with ~US$600m in the bank. That's quite a nice result.
I thought the Q&A went fairly easy on them, but it was interesting to see one of the analysts speak of "high single digit growth" (per annum was my reading) and US$940m annualised- which is US$235m/q (compared with the US$215m they reported). At this point they started throwing numbers around like $1.6b and $3b.
-----
I've included a chart which shows, in dollar terms, the quarterly change in US earnings. Sep-23 is not the first quarter where Illucix increased more than Pylarify, though I'd be interested to know why Pylarify had such a big jump in the Mar-23 quarter compared to Illucix.
But if you take out the first three quarters where only Pylarify was on market, Illucix captured 40% of the increase (Pylarify increased $US122.7m in the time Illucix increased to $US85.2m).
Assuming the other competitors don't capture much, then we can permit ourselves two optimistic predictions.
1) US TAM should reach $1.6b almost certainly, and $2b with a reasonable confidence (given TLX is predicting $2.3b and LNTH $3.0b and the analysts don't seem to be howling them down and telling them they're idiots)
2) TLX can quite reasonably be expected to capture 40% of the increase, which corresponds to an extra $40m/q in the $1.6b case and $80m/q in the $2b case.
![]()
- Forums
- ASX - By Stock
- Ann: Q3 2023 Business Update to Accompany Quarterly Results
Thanks @spnc, always good to see what the competition are...
Featured News
Add TLX (ASX) to my watchlist
|
|||||
Last
$18.35 |
Change
0.260(1.44%) |
Mkt cap ! $6.133B |
Open | High | Low | Value | Volume |
$18.05 | $18.40 | $18.03 | $12.42M | 679.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 53 | $18.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.38 | 306 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 593 | 19.260 |
1 | 625 | 18.950 |
2 | 378 | 18.900 |
1 | 1800 | 18.750 |
1 | 1 | 18.700 |
Price($) | Vol. | No. |
---|---|---|
17.440 | 2500 | 1 |
17.850 | 19 | 1 |
18.200 | 126 | 1 |
18.300 | 10 | 1 |
18.350 | 58 | 1 |
Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
SPONSORED BY The Market Online